Diabetic Macular Edema Anti-VEGF Treatment Response and Visceral Adiposity Index

298 patients with type 2 diabetes and center-involved diabetic macular edema (DME) initiating anti-VEGF therapy between January 2022 and December 2023. This retrospective cohort study analyzes the association between baseline Visceral Adiposity Index (VAI) scores and treatment resistance, with 47.0% of patients classified as non-responders.

Use Cases

• Train a logistic regression model to predict treatment resistance using baseline VAI scores and other confounders.
• Assess the prognostic performance of VAI for anti-VEGF resistance using ROC curve analysis with the reported AUC of 0.73.
• Perform Kaplan-Meier survival analysis on time-to-positive response, stratified by the optimal VAI cut-off of 2.50.
• Investigate the relationship between systemic metabolic dysfunction, measured by VAI, and localized treatment failure in DME.

Strengths

• Dataset includes 298 patient records from a defined clinical cohort.
• Analysis provides specific statistical results, including an Adjusted OR of 0.71 per VAI unit increase and an AUC of 0.73.
• Clear temporal coverage from January 2022 to December 2023.

Limitations

• Data is contained within a 16.3 KB DOCX file, indicating it is likely a summary table or manuscript text, not a structured, machine-readable dataset.
• The specific columns and raw patient-level data are unavailable, limiting direct analytical use.
• Sample is limited to 298 patients from a single retrospective study.

Provenance

Source

Author Mi Chen, published on figshare.

Collection Method

Retrospective cohort study of patients with type 2 diabetes and center-involved DME.

Time Range

January 2022 to December 2023.

Freshness

Data covers up to December 2023, with the record last updated in March 2026.

Geography

null